Vol.29, 2024 雅法全球生物医药交易周报 YAFO Weekly Global Wrap-up Report

学术   2024-09-22 10:39   菲律宾  

1. Summary of the week


9月14日到20日,全球医药市场共完成了14项授权和合作协议,中国医药市场占了3项,2项国内交易和1项引进交易。Altamira Therapeutics与优锐医药达成协议,将Bentrio独家授权范围扩展到东南亚和东亚的多个国家和地区。禾元生物授权贝达药业在约定区域内独家经销植物源重组人血清白蛋白注射液。惠升生物与华东医药就一类新药惠优静(加格列净片)在中国大陆的商业化权益达成独家战略合作。

在全球范围内,共签署了11项协议。其中最大的一项交易是Nippon Shinyaku引进Capricor Therapeutics一临床三期资产Deramiocel,首付款2000万美元,总价值7.35亿美元。

From September 14 to 20, 14 licensing and collaboration deals were signed globally. In the China Biotech Industry, Altamira Therapeutics secured an in-licensing agreement with Nuance Pharma for Bentrio®, expanding its reach across Southeast and East Asia. Additionally, Betta Pharmaceuticals signed a regional distribution agreement with Healthgen Biotechnology for plant-derived OsrHSA, and Huisheng Bio partnered with Huadong Medicine for the exclusive commercialization of Janagliflozin.

Globally, 11 licensing and cooperation agreements were finalized that week, with the largest being between Capricor Therapeutics and Nippon Shinyaku for the Phase III asset Deramiocel, valued at $735 million, which includes a $20 million upfront payment.

2. Licensing Deals








2a. China section









2b. Global section










3. M&A Deals








4. Top Deals of the year 2024




5. 2019-2023 China Innovative Drug Licensing Transactions


关于雅法资本(YAFO Capital)

雅法资本成立于2013年,作为新型投资和投行咨询机构,致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购,雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络,在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队,覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历,为客户交易提供强力支持。雅法总部位于上海,在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions.  For more information, please visit www.yafocapital.com


药通中国近期活动


Event Name

2024-09  药通中国秋季路演,线上&云南
2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan
2025-01 药通中国论坛@JPM,线上&旧金山
2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco

雅法全球生命科学
雅法生命科学是雅法资本旗下专注医疗健康领域的投行部门。雅法全球生命科学将与您定期分享优质的海外医疗项目及最新的全球医疗行业资讯与行业分析。
 最新文章